Concentrations of Formoterol in Blood and Urine

Blood and Urinary Concentrations of Inhaled Formoterol in Asthmatic Subjects and Elite Athletes With Asthma

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00914654

Enrollment

Registered

2009-06-05

Start date

2009-07-31

Completion date

2010-12-31

Last updated

2009-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

Asthma, Doping, Formoterol, Urinary concentrations, Beta-agonists

Brief summary

The purpose of the study is to assess the blood and urine concentrations of inhaled formoterol.

Detailed description

The purpose of the study is to assess the serum and urine concentrations after inhalation of 18 microgram formoterol as one dose. Furthermore to investigate the serum and urine concentrations of inhaled formoterol and evaluate the difference between three groups: healthy men, male asthmatic subjects and male elite athletes with asthma.

Interventions

DRUGinhaled formoterol

Inhalation of 18 microgram formoterol as one dose. Oxis Turbohaler 9 microg/dose, MA no. 30072.

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Physician-diagnosed asthma with positive reversibility or challenge test. * Informed consent. * Age between 18-45 years. * Sex: male. * Asthma classified as mild to moderate according to GINA guidelines. * Used beta-2-agonist in minimum 12 months.

Exclusion criteria

* Smokers or ex-smokers with a smoking history of 10 pack years or more. * Respiratory tract infections within the last 2 weeks prior to study day. * Subjects with other chronic diseases than asthma and allergy. * Allergy towards the study medicine. * Use of beta-2-agonist 10 days prior to study day.

Design outcomes

Primary

Measure	Time frame
Serum and urine concentrations of formoterol	baseline, 4, 8, and 12 hours after medicine administration

Countries

Denmark

Contacts

Primary ContactJimmi Elers, MD

jele0004@bbh.regionh.dk+45 35313208

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026